That can damage the cells lining the esophagus, prompting them to grow back with genetic mistakes.About 22,370 times a year in the United States, those mistakes culminate in cancer.Esophageal cancer ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a ...

Steroid injection combined with oral steroid therapy outperformed other steroid administrations for preventing esophageal stricture post-ESD.

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, ...

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

Eupraxia's EP-104GI is currently in a Phase 1b/2a trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of ...

which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis ("EoE"). New Clinical Data from the Fourth Cohort of the RESOLVE Trial The results announced ...